免疫效应细胞相关肠炎的组织学谱系与 T 细胞克隆性特征

Characterization of Histologic Spectrum and T-Cell Clonality in Immune Effector Cell-Associated Enteritis.

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

AML/MDS 细胞治疗的最新进展

Recent advances in cell therapy for AML/MDS.

辐照 CD19 嵌合抗原受体 YTS 细胞保留抗肿瘤活性并可作为自体 CAR-T 疗法的可规模化替代方案

Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy.

探索长期疾病控制：Axicabtagene Ciloleucel CAR-T 细胞治疗或异基因造血细胞移植治疗复发/难治性大 B 细胞淋巴瘤

In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relap

与 allo-HCT 相比，axi-cel 为 r/r LBCL 患者提供了更优的 PFS 和 OS，主要归因于治疗相关死亡率更低，以及在细胞治疗前对化疗难治性疾病患者的疾病控制得到改善。

CD19 与 BCMA 靶向 CAR-T 细胞治疗中输注前宿主骨髓易感性：克隆性造血、血液毒性与治疗相关髓系肿瘤

Pre-Infusion Host-Marrow Vulnerability in CD19- and BCMA-Directed CAR T-Cell Therapy: Clonal Hematopoiesis, Hematotoxicity, and Therapy-Related Myeloi

超越传统嵌合抗原受体：拓展 CAR-T 细胞疗法中的可靶向抗原版图

Beyond Conventional Chimeric Antigen Receptors: Expanding the Targetable Antigen Landscape in Chimeric Antigen Receptor-T Cell Therapy.

Idecabtagene Vicleucel 后 100 天内的感染及其对复发/难治性多发性骨髓瘤生存的影响：一项 CIBMTR 分析

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

BCMA/CD19 双靶向 CAR-T 细胞疗法用于新诊断多发性骨髓瘤老年患者：一项 1 期研究

BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.

CAR-T 细胞治疗前基于苯达莫司汀的淋巴细胞清除：一项系统综述

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.